Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, Florida, USA.
Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
World Neurosurg. 2021 Feb;146:e822-e828. doi: 10.1016/j.wneu.2020.11.027. Epub 2020 Nov 13.
Trigeminal neuralgia features jolts of pain along the distribution of the trigeminal nerve. If patients fail conservative management, microvascular decompression (MVD) is typically the next step in treatment. MVD consists of implanting a separating material, often Teflon, between the nerve and compressive lesions. A review found similar success and complication rates between Teflon and Ivalon, another commonly used material. The aim of this study was to analyze outcomes and complications associated with Teflon and Ivalon in MVD.
We conducted a 2-center retrospective cohort study of trigeminal neuralgia treated with MVD between 2005 and 2019. Patients with no postoperative follow-up were excluded. Postoperative pain was graded using the Barrow Neurological Institute (BNI) pain intensity score. Relapse was defined as a BNI score of 4-5 during follow-up after initial pain improvement or an initial BNI score of 1-3.
The study included 221 MVD procedures in 219 patients. Ivalon was implanted in 121 procedures, and Teflon was implanted in 100 procedures. Multivariate analysis found that implant type had no effect on final BNI score (P = 0.305). Relapse rates were similar at 5- and 10-year follow-up (5-year: Ivalon 10.7%, Teflon 18.0%, P = 0.112; 10-year: Ivalon 11.6%, Teflon 19.0%, P = 0.123). There was no difference in postoperative immediate facial numbness (P = 0.125). Postoperative hearing difficulty was higher in the Ivalon cohort (8.4% vs. 1.0%; P = 0.016).
We found no significant difference in final BNI score or risk of relapse between Ivalon and Teflon. Complications were similar, although Ivalon was more associated with temporary postoperative hearing loss.
三叉神经痛的特征是沿着三叉神经分布的阵发性疼痛。如果患者保守治疗失败,微血管减压术(MVD)通常是下一步治疗。MVD 包括在神经和压迫性病变之间植入分离材料,通常是特氟隆。一项综述发现,特氟隆和伊伐隆(另一种常用材料)的成功率和并发症发生率相似。本研究旨在分析 MVD 中特氟隆和伊伐隆的结果和并发症。
我们进行了一项 2 中心回顾性队列研究,纳入了 2005 年至 2019 年间接受 MVD 治疗的三叉神经痛患者。排除了无术后随访的患者。术后疼痛采用巴罗神经研究所(BNI)疼痛强度评分进行分级。复发定义为随访期间初始疼痛改善后 BNI 评分 4-5 或初始 BNI 评分 1-3。
该研究共纳入 219 例患者的 221 例 MVD 手术。121 例植入伊伐隆,100 例植入特氟隆。多变量分析发现植入物类型对最终 BNI 评分无影响(P=0.305)。5 年和 10 年随访的复发率相似(5 年:伊伐隆 10.7%,特氟隆 18.0%,P=0.112;10 年:伊伐隆 11.6%,特氟隆 19.0%,P=0.123)。术后即刻面部麻木无差异(P=0.125)。伊伐隆组术后听力困难发生率较高(8.4%比 1.0%;P=0.016)。
我们发现伊伐隆和特氟隆在最终 BNI 评分或复发风险方面没有显著差异。并发症相似,尽管伊伐隆更与术后暂时性听力损失相关。